NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens

AIDS Reviews

Volumn 4, Issue 3, 2002, Pages 128-139

  Joly, Véronique ^a   Descamps, Diane ^a   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral therapy; HIV; Non nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER METABOLISM; MEDICAL DECISION MAKING; MITOCHONDRION; MYOPATHY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIMARY HEALTH CARE; REVIEW; RISK; SALVAGE THERAPY; SIDE EFFECT; STEATOSIS; TREATMENT FAILURE; VIROLOGY; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TYPING;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 0036629840     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the IAS-USA panel. JAMA 2002;288:222-35.
2. Dybul M, Fauci A, Bartlett J, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the panel on clinical practices for treatment of HIV. MMWR 2002;51:1-55.
3. Staszewski S, Keiser P, Montaner J. et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults. JAMA 2001;285:1155-63.
4. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretrovira therapy in Swiss HIV Cohort Study. 7th CROI. San Francisco 2000 [abstract 57].
5. Ten Hofstede H, De Marie S, Foudraine N, Danner S, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-6.
6. Marcus K. Truffa M, Boxwell D, Toerner J. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: Cases from the FDA's Adverse Event Reporting System (AERS). 9th CROI. Seattle 2002 [abstract LB14].
7. Lonergan J, Behling C, Pfander H. Hassanein T, Mathews W. Hyperlactatemia and hepatic abnormalities in 10 HIV-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-6.
8. Mokrzycki M, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000;30:198-200.
9. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by NRTI is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999;354:1112-5.
10. Kakuda T, Brundage R, Anderson P, Fletcher C. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999;13:2311-2.
11. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of NRTI to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
12. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2003; In Press.
13. McComsey G, Lonergan T, Fisher R, et al. Improvements in lipoatrophy are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). 9th CROI. Seattle 2002 [abstract 701].
14. Carr A, Smith D, Workman C, et al. Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: a randomized, controlled, open-label, multicentre, 24-week study. 9th CROI. Seattle 2002 [abstract 32].
15. John M, James I. McKinnon E, et al. A randomized, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. 9th CROI. Seattle 2002 [abstract 700].
16. Shirasaka T, Kavlick M, Ueno T, et al. Emergence of HIV type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
17. Iversen A, Shafer R, Wehrly J, et al. Multidrug-resistance of HIV type 1 strains resulting from combination antiretroviral therapy. J Virol 1996;70:1086-90.
18. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistant mutations in HIV-1 reverse transcriptase gene in therapy naïve patients receiving stavudine plus didanosine combination therapy. STADI group. AIDS 1999;13:1705-9.
19. Winters M. Coolley K. Girard Y. et al. A 6-basepair insert in the reverse transcriptase of HIV type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998;102:1769-75.
20. Larder B, Bloor S, et al. A family of insertion mutations between codon 67 and 70 of HIV type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999;43:1961-7.
21. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of HIV type 1 variants with insertions and deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001;45:1836-42.
22. Lin P. Rose R, Samanta H, et al. Genotypic and phenotypic analysis of HIV type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170:1157-64.
23. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997;11:696-7.
24. Lin PF, González C, Griffith B, et al. Stavudine resistance: An update on susceptibility following prolonged therapy. Antiviral Ther 1999;3:21-8.
25. Coakley E, Hammer S, et al. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000;14:9-15.
26. De Mendoza C, Soriano V, Briones C, et al. Emergence of zidovudine resistance in HIV-1 infected patients receiving stavudine. J AIDS 2000;23:279-81.
27. Pozniak A, Gilleece Y, Nelson M, et al. Zidovudine genotypic and phenotypic resistance arising in patients never exposed to zidovudine. Antiviral Ther 2000;5(Suppl. 3):42.
28. Calves V, Mouroux M, Descamps D, et al. Occurrence of thymidine-associated mutations in naïve patients treated more than 6 months by stavudine/lamivudine bitherapy combination and tritherapies including stavudine/didanosine or stavudine: lamivudine. Antiviral Ther 2000;5(Suppl 3)40-1.
29. Moyle G, Gazzard B. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. AIDS 2000;15:799-800.
30. Pellegrin I, Garrigue I, Caumont A, et al. Persistence of zidovudine-resistant mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen. AIDS 2001;15:1071-3.
31. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine naïve patients experiencing viremia on stavudine containing regimen. AIDS Res Hum Retrovir 2001;17:1107-15.
32. Katlama C, Valantin M, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naïve and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1998;129:525-31.
33. Izopet J, Bicart-See A, Pasquier C, et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999;59:507-11.
34. Montaner J, Mo T, Raboud J, et al. HIV-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. J Infect Dis 2000;181:729-32.
35. Shulman N, Machekano R, Shafer R, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J AIDS 2001;27:377-80.
36. Demeter L, Nawaz T, Morse G, et al. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis 1995;172:1480-1485.
37. Shafer R, Winters M, Jellinger R, Merigan T. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis 1996;174:448-9.
38. Winters M, Shafer R, Jellinger R, et al. HIV reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997;41:757-62.
39. Resistance mutations project panel. International AIDS Society-USA Resistance Testing Guidelines Panel. Update on Drug Resistance Mutations in HIV-1. Topics in HIV Medicine 2001;9:91-3.
40. Meyer P, Matsuura S, So A, Scott W. Unblocking of chain terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998;95:13471-6.
41. Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of HIV type 1 selected during therapy. J Virol 1994;68:1660-8.
42. Byrnes V, Sardana V, Schleif W, et al. Comprehensive mutant enzyme and viral variant assessment of HIV type 1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1576-9.
43. Richman D, Shih C, Lowy I, et al. HIV type 1 mutants resistant to NNRTI arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-5.
44. Demeter L, Meehan P, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:136-44.
45. Montaner J, Reiss R, Cooper D, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998;279:930-7.
46. Staszewski S, Morales-Ramírez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73.
47. Murphy R, Katlama C, Johnson V. et al. The Atlantic Study: A randomized open-label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. 39th ICAAC. San Francisco 1999 [abstract LB-22].
48. Albrecht M, Bosch R, Hammer S, et al. Nelfinavir, efavirenz or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2000;345:398-407.
49. Larder B. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring HIV type 1 resistance to NNRTI. Antimicrob Agents Chemother 1992;36:2665-9.
50. Whitcomb J, Deks S, Huang W, et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1 infected patients. 7th CROI San Francisco 2000 [abstract 234].
51. Haubrich R, Whithcomb J, Keiser P, et al. NNRTI viral hypersensitivity is common and improves short term virological response. 4th International Workshop on HIV Drug Resistance and Treatment Strategies. Sitges, Spain, 2000 [abstract 87].
52. Shulman N, Zolopa A, Passaro D, et al. Phenotypic hypersusceptibility to NNRTI in treatment-experienced HIV-infected patients: impact on virological response to efavirenz based therapy. AIDS 2001;15:1125-32.
53. Mellors J, Vaida F, Bennett K, et al. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398. 9th CROI. Seattle. February 24-28, 2002 [abstract 45].
54. Frater A, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001;15:1493-502
55. Descamps D, Collin G, Letourneur F, et al. Susceptibility of HIV type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997;71:8893-8.
56. Cox S, Aperia K, Albert J, et al. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994;10:1725-9.
57. Tomasselli A, Hui J, Sawyer T, et al. Specificity and inhibition of proteases from HIV 1 and 2. J Biol Chem 1990;265:14675-83.
58. Vacca J, Dorsey B, Schleif W, et al. L-735,524: an orally bioavailable HIV type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
59. Collin G, Descamps D, Apetrei C, et al. Naturally occurring reduced susceptibility of HIV-2 to protease inhibitors. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998.
60. Witvrouw M, Pannecouque C, De Clercq E, et al. Susceptibility of HIV-2 to approved and experimental antiretroviral drugs: implications for treatment. Antiviral Therapy 20027:118.
61. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994;243:369-87.
62. Gutschina A, Weber IT. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteins proteases. Proteins 1991;10:325-9.
63. Shaharabany M, Hizi A. The catalytic functions of chimeric reverse transcriptases of HIV type 1 and type 2. J Biol Chem 1992;267:3674-8.
64. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced HIV disease who have had failure of combination nucleoside therapy. J Infect Dis 1998;177:1514-20.
65. Haas D, Fessel W, Delapenha R, et al. Therapy with efavirenz plus indinavir in patients with extensive prior NRTI experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2001;183:392-400.
66. Kuritzkes D, Bassett R, Johnson V, et al. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of ACTG protocol 370. AIDS 2000; 14:1553-8.
67. Kuritzkes D, Ickovics J, Bassett R, Hellmann N, Johnson V, for the ACTG 370 Protocol team. HIV-1 drug resistance and medication adherence in patients receiving NRTI. 5th International Workshop on HIV Drug Resistance and Treatment Strategies. Scottsdale, Arizona 2001 [abstract 84].
68. Katzenstein D, Shulman N, Bosch R, et al. Genetic correlates of phenotypic hypersusceptibility to efavirenz in highly nucleoside-experienced subjects in ACTG 364. The 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires [abstract 594].
69. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999;13:71-7.
70. Gulick R, Hu X, Fiscus S, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in HIV-infected adults with virologic failure on indinavir: AIDS Clinical Trial Group Study 359. J Infect Dis 2000;182:1375-84.
71. Fletcher C, Acosta E, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000;14:2495-501.
72. Deeks S, Hellmann N, Grant R, et al. Novel four-drug salvage treatment regimens after failure of a HIV type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999;179:1375-81.
73. Deeks S, Hecht F, Swanson M, et al. Virologic outcomes with protease inhibitor therapy in an urban AIDS clinic: relationship between baseline characteristics and response to both initial and salvage therapy. AIDS 1999;3:35-44.
74. Gulick R, Smeaton L, D'Aquila R, et al. Indinavir, nevirapine, stavudine and lamivudine for HIV-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis 2001;183:715-21.
75. Benson C, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in HIV type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
76. Negredo E, Bonjoch A, Sirera G, et al. NEKA study: NRTI-sparing regimen. XIV International AIDS Conference. Barcelona, July 2002 [abstract LbPe B 9021].
77. Danner S, Brun S, Richards B, et al. Kaletra (lopinavir/ritonavir) and efavirenz 72-week safety and efficacy evaluation in multiple PI-experienced patients. 41st ICAAC. Chicago 2001 [abstract 1925].
78. Hammer S, Vaida F, Bennett K, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002;288:169-80.
79. Justesen U, Klitgaard N, Brosen K, Petersen C. Amprenavir is an effective inducer of delavirdine metabolism: a steady-state pharmacokinetic interaction study between amprenavir and delavirdine in healthy volunteers. 9th CROI. Seattle 2002 [abstract 442-W].
80. Moreno A, Casado JL, Marti-Belda P, et al. Concomitant use of NNRTI does not decrease the inhibitory quotient of dual ritonavir/indinavir-based therapy. 41st ICAAC. Chicago 2001; [abstract I-1728].
81. Piliero P, Preston S, Japour A, Stevens R, Morvillo C, Drusano G. Pharmacokinetics of the combination of ritonavir plus saquinavir with and without efavirenz in healthy volunteers. 41st ICAAC. Chicago 2001 [abstract A-495].
82. Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in HIV-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002;46:570-4.
83. O'Mara E, Agarwala S, Randall D, Geraldes M, Stolz R, Mummaneni V. Steady-state pharmacokinetic-interaction study of atazanavir with efavirenz and ritonavir in healthy subjects. 9th CROI. Seattle 2002 [abstract 444-W].
84. Hoover M, Mayer D, Wentworth D, et al. Non-nucleoside reverse transcriptase inhibitor phenotypic and genotypic resistance in patients with virological failure during salvage therapy: 12-week outcome data from the GART study (CPCRA 046). 5th International Workshop on HIV Drug Resistance and Treatment Strategies 2001. Scottsdale, Arizona [abstract 105].
85. Casado JL, Hertogs K, Ruiz L, et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000;14:1-7.
86. Eshleman S, Krogstad P, Jackson J, et al. Analysis of HIV type 1 drug resistance in children receiving NRTI plus nevirapine, nelfinavir or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 2001:183:1732-8.